SQZB — SQZ Biotechnologies Co Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $1.18m
- -$9.01m
- $21.48m
Annual income statement for SQZ Biotechnologies Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.7 | 20.1 | 21 | 27.1 | 21.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 33.1 | 54.4 | 72.1 | 95.9 | 102 |
| Operating Profit | -20.4 | -34.3 | -51.1 | -68.8 | -80.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.3 | -32.2 | -50.5 | -68.7 | -79.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19.3 | -32.2 | -50.5 | -68.7 | -79.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.3 | -32.2 | -50.5 | -68.7 | -79.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.2 | -32.2 | -50.5 | -68.7 | -79.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.844 | -1.34 | -2.04 | -2.49 | -2.59 |
| Dividends per Share |